BRAF/MEK Combo Approved for Melanoma

Abstract

The FDA approved the BRAF/MEK inhibitor combination encorafenib/binimetinib for patients with metastatic or inoperable melanoma with a BRAF V600E or V600K mutation. The approval was based on results of a phase III trial in which patients treated with the combination had a median progression-free survival of 14.9 months, compared with 7.3 months in a control group that received vemurafenib alone.